Novo Nordisk shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot CagriSema. The medicine helped patients with diabetes lose 15.7% of their weight over 68 weeks, compared with 3.1% with placebo, Novo said Monday. Investors hoped to see the final figure closer to 20%. Sam Fazeli reports. (Source: Bloomberg)
